Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 1/2024

Open Access 26-11-2022 | Short Communication

Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)

Authors: Robert S. Rosenson, J. Antonio G. López, Maria Laura Monsalvo, You Wu, Huei Wang, Santica M. Marcovina

Published in: Cardiovascular Drugs and Therapy | Issue 1/2024

Login to get access

Abstract

Purpose

Cholesterol in lipoprotein(a) [Lp(a)-C] is commonly estimated as 30% of the measured Lp(a) mass. However, difficulties in the accurate measurement of Lp(a) mass, along with the inaccuracy of the 30% assumption, produce erroneous values when LDL-C is corrected for Lp(a) [LDL-CLp(a)corr]. Our aim was to develop a new formula for LDL-CLp(a)corr to reduce this error.

Methods

We developed a new formula to calculate Lp(a)-C from the molar measurement of Lp(a), which is Lp(a) nmol/L × 0.077 = Lp(a)-C mg/dL. The calculated Lp(a)-C is subtracted from LDL-C to obtain LDL-CLp(a)corr. The results obtained with our novel formula versus the conventional formula were compared in 440 samples from 239 participants enrolled in the BANTING study.

Results

With the conventional formula, approximately 7% of samples with low LDL-C resulted in negative LDL-CLp(a)corr values. With the new formula, no negative LDL-CLp(a)corr values occurred. Among groups with the highest Lp(a)/apoB ratio (p < 0.001) and smaller apolipoprotein(a) isoform size (p < 0.006), LDL-CLp(a)corr was significantly underestimated by the conventional formula, which may result in the undertreatment of some patients.

Conclusion

The new formula provides more reliable estimates of LDL-CLp(a)corr than the conventional formula.
Trial registration: ClinicalTrials.gov NCT02739984.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–46.CrossRefPubMedPubMedCentral Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–46.CrossRefPubMedPubMedCentral
2.
go back to reference Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH. Human plasma lipoprotein(a): structural properties. J Biol Chem. 1983;258:4582–9.CrossRefPubMed Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH. Human plasma lipoprotein(a): structural properties. J Biol Chem. 1983;258:4582–9.CrossRefPubMed
3.
go back to reference Yeang C, Witztum JL, Tsimikas S. ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26:169–78.CrossRefPubMed Yeang C, Witztum JL, Tsimikas S. ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26:169–78.CrossRefPubMed
4.
go back to reference Zheng W, Chilazi M, Park J, Sathiyakumar V, Donato LJ, et al. Assessing the accuracy of estimated lipoprotein(a) cholesterol and lipoprotein(a)-free low-density lipoprotein cholesterol. J Am Heart Assoc. 2022;11:e023136.CrossRefPubMedPubMedCentral Zheng W, Chilazi M, Park J, Sathiyakumar V, Donato LJ, et al. Assessing the accuracy of estimated lipoprotein(a) cholesterol and lipoprotein(a)-free low-density lipoprotein cholesterol. J Am Heart Assoc. 2022;11:e023136.CrossRefPubMedPubMedCentral
5.
go back to reference Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomized controlled BANTING study. Diabetologia. 2019;62:948–58.CrossRefPubMedPubMedCentral Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, et al. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomized controlled BANTING study. Diabetologia. 2019;62:948–58.CrossRefPubMedPubMedCentral
7.
go back to reference Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436–9.CrossRefPubMed Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436–9.CrossRefPubMed
8.
go back to reference Yang CY, Gu ZW, Weng SA, Chen SH, et al. Structure of apolipoprotein B-100 of human low density lipoproteins. Arteriosclerosis. 1989;9:96–108.CrossRefPubMed Yang CY, Gu ZW, Weng SA, Chen SH, et al. Structure of apolipoprotein B-100 of human low density lipoproteins. Arteriosclerosis. 1989;9:96–108.CrossRefPubMed
9.
go back to reference Hokanson J, Austin M, Brunzell J. Measurement and clinical significance of low density lipoprotein subclasses. In: Handbook of lipoprotein testing. Rifai N, Warnick G, Dominiczak M (eds). Washington, DC: AACC. 1997;267–82. Hokanson J, Austin M, Brunzell J. Measurement and clinical significance of low density lipoprotein subclasses. In: Handbook of lipoprotein testing. Rifai N, Warnick G, Dominiczak M (eds). Washington, DC: AACC. 1997;267–82.
10.
go back to reference Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8.CrossRefPubMed Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5:540–8.CrossRefPubMed
11.
go back to reference Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48–e60. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48–e60.
12.
go back to reference Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053.CrossRefPubMedPubMedCentral Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053.CrossRefPubMedPubMedCentral
13.
go back to reference Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035–46.CrossRefPubMed Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035–46.CrossRefPubMed
14.
go back to reference Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e143. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e143.
15.
go back to reference Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.CrossRefPubMed Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.CrossRefPubMed
Metadata
Title
Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a)
Authors
Robert S. Rosenson
J. Antonio G. López
Maria Laura Monsalvo
You Wu
Huei Wang
Santica M. Marcovina
Publication date
26-11-2022
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 1/2024
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-022-07407-y

Other articles of this Issue 1/2024

Cardiovascular Drugs and Therapy 1/2024 Go to the issue